BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 20160358)

  • 1. Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
    Peroja P; Pedersen M; Mantere T; Nørgaard P; Peltonen J; Haapasaari KM; Böhm J; Jantunen E; Turpeenniemi-Hujanen T; Rapakko K; Karihtala P; Soini Y; Vasala K; Kuittinen O
    Sci Rep; 2018 Oct; 8(1):14814. PubMed ID: 30287880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinctive cell properties of B cells carrying the BCL2 translocation and their potential roles in the development of lymphoma of germinal center type.
    Sakai T; Nishikori M; Tashima M; Yamamoto R; Kitawaki T; Takaori-Kondo A; Suzuki T; Tsuzuki S; Uchiyama T
    Cancer Sci; 2009 Dec; 100(12):2361-7. PubMed ID: 19780757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact.
    Devin J; Kassambara A; Bruyer A; Moreaux J; Bret C
    J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31336593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.
    Roberson PL; Smith LB; Morgan MA; Schipper MJ; Wilderman SJ; Avram AM; Kaminski MS; Dewaraja YK
    Cancer Biother Radiopharm; 2017 Nov; 32(9):309-319. PubMed ID: 29083933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin Lymphoma (NHL) in Pakistan.
    Pervez S
    Int J Mol Cell Med; 2012; 1(1):62-3. PubMed ID: 24551760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma.
    Küçükzeybek BB; Bener S; Çallı AO; Paksoy TD; Payzin B
    Turk J Haematol; 2013 Sep; 30(3):275-82. PubMed ID: 24385807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary bone diffuse large B-cell lymphoma: clinicopathologic study of 21 cases and review of literature.
    Bhagavathi S; Micale MA; Les K; Wilson JD; Wiggins ML; Fu K
    Am J Surg Pathol; 2009 Oct; 33(10):1463-9. PubMed ID: 19675454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
    Winter JN
    Curr Hematol Malig Rep; 2007 Oct; 2(4):235-41. PubMed ID: 20425375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.
    Ye Q; Xu-Monette ZY; Tzankov A; Deng L; Wang X; Manyam GC; Visco C; Montes-Moreno S; Zhang L; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Parsons BM; Møller MB; Piris MA; Winter JN; Medeiros LJ; Hu S; Young KH
    Oncotarget; 2016 Jan; 7(3):2401-16. PubMed ID: 26573234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin's lymphoma.
    Pervez S; Nasir MI; Moatter T; Ahsan A; Haq A; Siddiqui T
    J Cancer Res Ther; 2009; 5(4):254-62. PubMed ID: 20160358
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.